IPPS to launch fifth 100 Days Mission Implementation Report in Paris

January 7, 2026

Hybrid Event | Tuesday 27 January 2026 | Paris, France and livestreamed via Zoom

Hosted by the International Pandemic Preparedness Secretariat (IPPS) in partnership with ANRS MIE/Inserm and the Pasteur Network 

Click here to register to attend virtually 

 

About the launch 

On 27 January 2026, IPPS will host the global launch of the Fifth Implementation Report of the 100 Days Mission, convened in Paris in collaboration with the French National Research Agency for HIV, Viral Hepatitis, Tuberculosis and Emerging Infectious Diseases (ANRS MIE/Inserm) and the Pasteur Network. This year’s report assesses progress throughout 2025 against a backdrop of multiple outbreaks, including H5N1, Dengue, Chikungunya, Ebola, Rift Valley Fever, and resurgent measles and pertussis, alongside the continued mpox health emergency in Africa. 

As the world moves toward major milestones in 2026, including France’s G7 Presidency, the One Health Summit, and the UN High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR), the Fifth Implementation Report asks a central question: Are we closer to ensuring rapid, equitable access to diagnostics, therapeutics and vaccines (DTVs) within 100 days of a newly detected pandemic threat? 

This event will: 

  • Publicly launch the 2025 Implementation Report and 100 Days Mission Scorecard 3.0, outlining progress in DTV development and priority actions for 2026. 
  • Strengthen cross-pillar alignment across diagnostics, therapeutics, vaccines, clinical trials and regulatory systems. 
  • Catalyse collaboration around the Therapeutics Development Coalition (TxDC) ahead of its Spring 2026 launch. 
  • Build consensus around investment and innovation priorities emerging from the 2025 Global Diagnostics Gap Assessment. 
  • Advance dialogue on vaccine equity, regional production and distributed manufacturing. 
  • Illustrate the societal value of preparedness, from innovation and job creation to strengthened health systems. 

The event will be hybrid and livestreamed via Zoom. Register for virtual attendance here. 

 

Programme 

All times shown in Central European Time (CET) 

You can view biographies for all of our speakers here [PDF].

 

09:00–09:30
Welcome & Opening Remarks 

Speakers:

  • Dr Mona Nemer, Chair of IPPS; Chief Science Advisor of Canada 
  • Prof Didier Samuel, Chairman and CEO of Inserm 
  • Dr Yazdan Yazdanpanah, Director of ANRS MIE  
  • Dr Rebecca Grais, Executive Director, Pasteur Network  
  • Ms Anne-Claire Amprou, Global Health Ambassador France 
09:30–10:30 – Session 1 
100 Days Mission Fifth Implementation Report Findings 

This session brings together members of the IPPS Science & Technology Expert Group (STEG) and IPPS Steering Group to present the key findings of the Fifth Implementation Report. Speakers will examine how diagnostics, therapeutics, vaccines, clinical trials and regulatory systems must work in concert—not in silos—to accelerate innovation and deployment. 

Speakers:

  • Ms Shingai Machingaidze, IPPS STEG Co-chair; Head of Africa Strategy and Engagement at CEPI (moderator) 
  • Dr Victor Dzau, IPPS STEG Co-chair; President, US National Academy of Medicine 
  • Dr Lindsay Keir, Incoming Programme Director, G20 & G7 Health and Development Partnership /   Former Director of Science and Policy, Impact Global Health 
  • Dr François Lacoste, IPPS STEG; Executive Vice President, Medical and Scientific Affairs, Institut Mérieux 
  • Dr Hala Audi, IPPS STEG; Business Strategy, Investment and R&D Partnerships at Quantoom Biosciences 
  • Dr Moeketsi Modisenyane, Director of Global Health, National Department of Health, South Africa (virtual) 
10:30–10:45 – Refreshment Break 

10:45–11:45 – Session 2 
Closing the Gap in R&D: Building a Global Development Coalition for Therapeutics 

Therapeutics remain one of the most underdeveloped components of the 100 Days Mission. This session will outline the goals of the Therapeutics Development Coalition (TxDC) and highlight how a coordinated global approach can accelerate antiviral innovation, strengthen collaboration, and support equitable access. 

Speakers:

  • Dr Victor Dzau, IPPS STEG Co-chair; President, US National Academy of Medicine (Moderator) 
  • Dr Philippe Duneton, Executive Director of Unitaid (Moderator) 
  • Dr Lynda Stuart, IPPS STEG; Fund for Science and Technology 
  • Ms Daphne von Buxhoeveden, Head of Unit for Policy and Coordination, European Commission   
  • Dr Ruxandra Draghia-Akli, IPPS STEG; Head of R&D, Novavax Inc 
  • Dr Kelly Chibale, IPPS STEG; Professor of Organic Chemistry, University of Cape Town, H3D Centre (virtual) 
11:45–12:45 – Session 3 
Diagnostics: The First Line of Defence for Health 

Drawing from the 2025 Global Diagnostics Gap Assessment, this panel will explore how to close persistent gaps in funding, coordination, innovation, and deployment. Speakers will discuss how diagnostics can be better integrated with vaccines and therapeutics for a coherent preparedness architecture. 

Speakers:

  • Dr Mona Nemer, Chair of IPPS; Chief Science Advisor of Canada (moderator) 
  • Dr Dayo Adetifa, CEO, FIND  
  • Dr Beth Cameron, Senior Adviser, Brown University Pandemic Centre; HLIP 
  • Dr Jilian Sacks, Global Health Policy Director, Roche Diagnostics 
  • Prof Bruno Lina, Président du Infectious Diseases Cluster 
  • Prof Leo Poon, Co-Director, Hong Kong University (HKU)- Pasteur 
  • Dr Hervé Raoul, Deputy Director, ANRS MIE 
12:45–13:45 – Lunch Break 

13:45–14:45 – Session 4 
Turning Innovation into Impact: Advancing Vaccine Equity 

This session examines how scientific innovation can be translated into equitable vaccine access, with a focus on regional production, distributed manufacturing, and the new Global Coalition on Regional Production, Innovation and Access. 

Speakers:

  • Dr Rick Bright, IPPS STEG; Bright Global Health (moderator) 
  • Prof Mario Santos Moreira, IPPS Steering Group; Pasteur Network; Fiocruz 
  • Dr Melanie Saville, Chief Scientific Officer, PATH 
  • Dr Eric Quéméneur, Director of France Vaccins, Inserm 
  • Dr Aurélia Nguyen, Deputy CEO, CEPI 
  • Dr Katherine Theiss Nyland, Senior Director Global Real World Evidence & Health Outcomes, GSK 
14:45–15:45 – Session 5 
From Global Commitment to Local Prosperity: Driving Impact Through Preparedness 

Preparedness drives long-term societal value—from innovation ecosystems and job creation to resilient health systems. This session explores how investments in DTVs and emerging technologies can deliver national benefits while strengthening global readiness. 

Speakers:

  • Ms Eloise Todd, Executive Director, Resilience Action Network International (rani) (moderator) 
  • Ms Shingai Machingaidze, IPPS STEG Co-chair; Head of Africa Strategy and Engagement at CEPI 
  • Dr Kerri Elgar, Senior Policy Analyst (Global Health & Development) OECD 
  • Prof Claude Muvunyi, Director General, Rwanda Biomedical Centre
  • Dr Claire Rieux, Medical Director, Médecins Sans Frontières France 
15:45–16:00 — The Way Forward 
Closing remarks from Dr Mona Nemer, Chair of IPPS and Chief Science Advisor of Canada 
Contact 
  • General enquiries: info@ippsecretariat.org